Antineoplastic Agents, Hormonal
"Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
| Descriptor ID |
D018931
|
| MeSH Number(s) |
D27.505.954.248.169
|
| Concept/Terms |
Antineoplastic Agents, Hormonal- Antineoplastic Agents, Hormonal
- Hormonal Agents, Antineoplastic
- Hormonal Antineoplastic Agents
- Hormonal Antineoplastics
- Antineoplastic Hormonal Drugs
- Drugs, Antineoplastic Hormonal
- Hormonal Drugs, Antineoplastic
- Hormonal Antineoplastic Drugs
- Antineoplastics, Hormonal
- Antineoplastic Hormonal Agents
- Agents, Antineoplastic Hormonal
- Antineoplastic Drugs, Hormonal
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Hormonal".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Hormonal".
This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in this website by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 2 | 2 | 4 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles.
-
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. Sci Rep. 2022 02 04; 12(1):1972.
-
Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer. Cell Commun Signal. 2020 09 18; 18(1):154.
-
Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution. Clin Breast Cancer. 2020 12; 20(6):520-526.
-
Medroxyprogesterone Acetate Prevention of Cervical Cancer through Progesterone Receptor in a Human Papillomavirus Transgenic Mouse Model. Am J Pathol. 2019 12; 189(12):2459-2468.
-
Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? J Cancer Surviv. 2018 06; 12(3):348-356.
-
Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells. Mol Cell. 2017 Mar 16; 65(6):1122-1135.e5.
-
Recurrence of cervical cancer and its resistance to progestin therapy in a mouse model. Oncotarget. 2017 Jan 10; 8(2):2372-2380.
-
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A. 2016 10 25; 113(43):E6600-E6609.
-
Alcohol Regulates Genes that Are Associated with Response to Endocrine Therapy and Attenuates the Actions of Tamoxifen in Breast Cancer Cells. PLoS One. 2015; 10(12):e0145061.
-
The changing role of ER in endocrine resistance. Breast. 2015 Nov; 24 Suppl 2:S60-6.